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Abstract
Malaria in pregnancy is one of the major causes of maternal morbidity and adverse birth outcomes.
In high transmission areas, its prevention has recently changed, moving from a weekly or bimonthly
chemoprophylaxis to intermittent preventive treatment (IPTp). IPTp consists in the administration
of a single curative dose of an efficacious anti-malarial drug at least twice during pregnancy –
regardless of whether the woman is infected or not. The drug is administered under supervision
during antenatal care visits. Sulphadoxine-pyrimethamine (SP) is the drug currently recommended
by the WHO. While SP-IPTp seems an adequate strategy, there are many issues still to be explored
to optimize it. This paper reviewed data on IPTp efficacy and discussed how to improve it. In
particular, the determination of both the optimal number of doses and time of administration of
the drug is essential, and this has not yet been done. As both foetal growth and deleterious effects
of malaria are maximum in late pregnancy women should particularly be protected during this
period. Monitoring of IPTp efficacy should be applied to all women, and not only to primi- and
secondigravidae, as it has not been definitively established that multigravidae are not at risk for
malaria morbidity and mortality. In HIV-positive women, there is an urgent need for specific
information on drug administration patterns (need for higher doses, possible interference with
sulpha-based prophylaxis of opportunistic infections). Because of the growing level of resistance of
parasites to SP, alternative drugs for IPTp are urgently needed. Mefloquine is presently one of the
most attractive options because of its long half life, high efficacy in sub-Saharan Africa and safety
during pregnancy. Also, efforts should be made to increase IPTp coverage by improving the
practices of health care workers, the motivation of women and their perception of malaria
complications in pregnancy. Because IPTp is not applicable in early pregnancy, which is a period
when malaria may also be deleterious for women and their offspring, there is a necessity to
integrate this strategy with other preventive measures which can be applied earlier in pregnancy
such as insecticide-treated nets.
Background
For a long time, malaria in pregnancy has been associated
with a range of deleterious effects in women and their off-
spring. It has been recognized as a public health priority
since the beginning of the 1980s. Currently, it is estimated
that each year more than 25 million women become preg-
Published: 4 December 2007
Malaria Journal 2007, 6:160 doi:10.1186/1475-2875-6-160
Received: 11 October 2007
Accepted: 4 December 2007
This article is available from: http://www.malariajournal.com/content/6/1/160
© 2007 Briand et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Malaria Journal 2007, 6:160 http://www.malariajournal.com/content/6/1/160
Page 2 of 7
(page number not for citation purposes)
nant in malaria endemic areas – mostly in sub-Saharan
Africa – and 75,000 to 200,000 infant deaths are attribut-
able to malaria infection in pregnancy [1,2].
The severity of clinical manifestations is determined by
the level of immunity before pregnancy, which depends
on the intensity and stability of malaria transmission. In
low and/or unstable transmission areas, the degree of
acquired immunity of women prior to pregnancy is low,
and both the mother and her foetus are at risk for the most
severe consequences of the infection. Malaria infections
are symptomatic, and the current strategy is to treat every
malarial access effectively. In contrast, in areas of high
malaria transmission (as in sub-Saharan Africa), women
have acquired a protective immunity prior to pregnancy.
Malaria infections are generally asymptomatic and the
strategy is based on the prevention of infections. Since the
early 2000's, prevention has been based on intermittent
preventive treatment (IPTp) and insecticide-treated bed
nets (ITNs) [1].
The introduction of IPTp was a turning point in the pre-
vention of malaria during pregnancy in high transmission
areas. This paper aimed to critically review available data
on its efficacy and effectiveness.
Consequences of malaria in pregnancy
In high transmission areas, malaria is associated with
maternal anaemia – potentially responsible for maternal
death when severe – and low birth weight (LBW) due to
both prematurity and intrauterine growth retardation [3].
LBW is a high risk factor for perinatal death and it is also
correlated with morbidity and mortality during infancy
[4,5]. A recent study estimated that malaria may contrib-
ute to 3–5% of maternal anaemia, 8–14% of LBW, and 3–
8% of infant mortality [2]. Malaria consequences are par-
ticularly deleterious in women co-infected with HIV, as
they have more frequently clinical and placental malaria,
more detectable malaria parasitaemia and higher malaria
parasite densities. HIV-positive women of all gravidities
are at increased risk, although primi- and secundigravidae
are the most affected overall [6].
Malaria during pregnancy may also influence the develop-
ment of antimalarial immunity during the first years of
life. Infants born to placenta-infected mothers were
shown to be more likely to develop a malaria infection
between four and six months of life, compared to those
born to non-infected mothers [7]. Recently, similar results
were obtained in a different malaria-endemic area [8]. It
was suggested that offspring of placental-infected multi
gravid women had the highest risk of parasitaemia during
the first years of life compared to children of primigravid
and/or placental non-infected women.
Strategies to prevent malaria during pregnancy
In Africa, the first malaria preventive strategies were
implemented in the 1950s. They consisted in weekly or
bi-monthly chemoprophylaxis with chloroquine (CQ) in
West African countries and dapsone-pyrimethamine or
sulphadoxine-pyrimethamine (SP) in East African coun-
tries. A large number of trials demonstrated the efficacy of
such a chemoprophylaxis in preventing LBW, maternal
anaemia and placental malaria infection [9,10]. Unfortu-
nately, because of the growing resistance of parasites to
these drugs and the poor compliance of the women with
the treatment the strategies finally showed a low efficacy.
In 1998 it was proposed, then finally implemented in
2004, that chemoprophylaxis should no longer be recom-
mended, but replaced by intermittent preventive treat-
ment for all pregnant women living in areas of stable
malaria transmission [1].
IPTp consists in the administration of a single curative
dose of an efficacious anti-malarial drug at least twice dur-
ing pregnancy – regardless whether or not the woman is
infected. The drug is administered under supervision dur-
ing antenatal care (ANC) visits. Sulphadoxine-pyrimeth-
amine is the drug currently recommended by the WHO
because of its safety and efficacy in pregnancy [1]. Several
studies have shown the high efficacy of IPTp with SP,
compared to placebo or CQ prophylaxis, on placental
infection, LBW and/or severe maternal anaemia [11-19].
IPTp with sulphadoxine-pyrimethamine: efficacy 
and effectiveness
While IPTp has been shown to be a promising strategy in
terms of efficacy and acceptability, some issues should be
adressed.
How many IPTp doses should women receive?
WHO recommends the administration of at least two
doses of SP during pregnancy [1]. This recommendation
was based on the average number of ANC visits women
had in African countries, and on the results of the first
IPTp studies [11,12,16]. While two doses were found
more efficacious than a single dose [16-20], few studies
have investigated the efficacy of a higher number of
intakes. These studies showed that three or more SP doses
were more efficacious than two in HIV-positive women,
but that no benefit was found in HIV-negative women
[16,18,21]. However, in all these studies but one [16] the
results might have been biased as the number of doses the
women received was not randomized but depended on
how often the women attended for ANC visits.
Hence, the efficacy of a higher number of IPTp doses is
still to be evaluated both in HIV-negative and HIV-posi-
tive women. These evaluations should be done in the con-
text of ITN use. ITN is the only strategy to be used duringMalaria Journal 2007, 6:160 http://www.malariajournal.com/content/6/1/160
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the first trimester of pregnancy, when malaria may also be
deleterious for women and their offspring [22]. IPTp is
not applicable at that time, because most antimalarial
drugs are contraindicated (due to possible toxicity on the
foetus) and most women do not attend ANC visits. In
addition to their additive effect [23], it was suggested that
the ITN and IPTp strategies could even be synergistic [13].
Also, the optimal number of doses should be evaluated in
terms of applicability. IPTp coverage with a full two-dose
treatment, which is the strategy recommended by almost
all countries with an IPTp policy, is still low. The admin-
istration of a higher number of doses may be difficult to
implement. Further studies are required to assess the
safety of administering more doses of SP in pregnant
women [16,21].
When should women receive IPTp?
WHO recommends that the first dose should be adminis-
tered at the first ANC visit after quickening – which
ensures that the woman is in the second trimester of preg-
nancy [1]. Following IPTp doses should be given at least
one month apart. There is currently no precision regard-
ing the best timing for their administration as it entirely
depends on the timing and frequency of ANC visits of the
woman. When applicable, women should particularly be
protected in late pregnancy, when both foetal growth [24]
and deleterious effects of malaria are most important
[23,25]. In the absence of ANC visits in the two first tri-
mesters, it could still be worthwhile to administer IPTp
even only in the last month of pregnancy. The baby is still
growing and has to be protected, and there is no major
contraindication in using SP close to delivery. A single
study found an increased risk of kernicterus in neonates
treated with sulphonamides [26], but this has not been
further confirmed [27]. Two recent studies highlighted the
relevance of a protection in late pregnancy [19,21]. Van
Eijk et al found that IPTp had a higher efficacy when the
last dose was administered close to delivery [19]. Simi-
larly, Filler et al showed a better protection in women ran-
domized in a SP-monthly group, who received their last
dose of SP close to delivery, than in women taking the
usual two-dose SP-IPTp [21].
The timing of drug administration should be taken into
account when evaluating IPTp efficacy. If key moments
are identified, women could be strongly encouraged to
attend for ANC visits precisely at these times. More funda-
mental studies are also needed to determine the optimal
dosing interval by clarifying how IPTp works (i.e., prophy-
lactic or treatment effect) and by providing pharmacoki-
netic data in pregnant women for SP [28].
Which women should receive IPTp?
WHO recommends that pregnant women of all gravidities
should receive IPTp [1]. However, most IPTp studies have
been limited to primi- and secundigravidae because their
offspring have the highest malaria morbidity [29]. A
recent study, specifically conducted in multigravidae, did
not show any beneficial effect of IPTp on anaemia or LBW
in this population of women [30].
The reliability of targeting the intervention to primi- and
secundigravidae only is questionable. For equity reasons,
it is hardly conceivable to exclude some women from
receiving a preventive measure (or public health interven-
tion). When implementing the intervention, it would be
difficult to identify precisely the women who have the
highest risk (i.e primi- and secundigravidae, plus HIV-
infected women of all gravidities), to single them out and
protect them specifically. Indeed, obstetrical histories are
difficult to collect, especially with regard to events such as
abortions or stillbirths, and the HIV status of a woman is
generally not known. Furthermore, while malaria has a
lower impact in multigravidae, it has not yet been fully
assessed how deleterious malaria is in women who have
been protected during their first pregnancies [31]. A recent
study strengthened the need for multigravidae to be effec-
tively protected as it suggested that their offspring, when
the placenta was infected, had a higher risk of parasitae-
mia during infancy compared to primigravidae [8].
IPTp effectiveness
While, by 2010, 80% of all pregnant women living in high
transmission areas are expected to receive IPTp [32], the
coverage of the intervention is still low. In Kenya, one of
the first countries to implement IPTp, the national cover-
age with two doses of SP was only 4% five years after IPTp
implementation [33]. Only one country (Malawi) is close
to achieving the 2000 Abuja target of 60% coverage of
pregnant women by 2005.
WHO advises that IPTp should be administered through
ANC services. Although ANC attendance is high in most
countries with IPTp policy (median, 2.0–4.8 ANC visits
per woman), it has not been sufficient to ensure a high
IPTp coverage. Several factors, such as women's percep-
tions and the practices of health-care workers, have been
identified to explain the poor compliance with IPTp
[33,34]. As an example, in an ongoing clinical trial con-
ducted in Benin, which aims to compare the efficacy of SP
versus mefloquine (MQ) for IPTp [35], it was found that
30% of the women did not attend the maternity clinic to
receive the second dose, and 40% continued to receive CQ
during the first trimester although the IPTp strategy has
been extensively explained to the women and midwives
participating to the trial (Briand, personal communica-
tion).Malaria Journal 2007, 6:160 http://www.malariajournal.com/content/6/1/160
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IPTp has been shown to be an efficacious strategy. How-
ever, a theoretically efficacious measure is not worthwhile
if it is not well applied in the field. Anthropological stud-
ies and knowledge, attitudes and practices surveys should
help to improve the implementation of IPTp by improv-
ing the understanding of women's and the motivation of
health-care workers. Furthermore, pragmatic studies are
required to assess the efficacy of IPTp in "real life" condi-
tions.
Should malaria prevention strategies change?
Because of the growing level of resistance of parasites to
SP, there are concerns about how long IPTp with SP, as
currently recommended by the WHO, will remain useful.
Resistance to SP has been first described several years ago
in East-Africa, and it is rapidly spreading in West Africa
[36]. In Benin, where IPTp has recently been imple-
mented, the resistance rate to SP was found to be around
50% in children under five years of age living in a semi-
rural area [37].
While it is likely that SP will have soon to be replaced by
a more effective antimalarial drug, it is not clear when this
change will become necessary. Recently, it was shown that
SP could keep its efficacy in public health applications
(such as intervention on birthweight or anaemia) in spite
of an impaired anti-parasite activity [38]. In the future, the
decision of switching to a more efficacious antimalarial
drug than SP should be based on the association of several
indicators, clinical as well as more directly related to the
drug. For this purpose, an active monitoring of pregnant
women in selected sentinel sites will probably be neces-
sary.
Which indicators should be used?
Low birth weight, defined as below 2,500 g, is the main
clinical indicator of the consequences of gestational
malaria. It is a strong predictor of infant health [4,5], eas-
ily measurable and reproducible, so it can be compared
between studies and countries. The only problem with
LBW is that, being multifactorial, it may require very large
samples to evidence differences between groups.
Maternal anaemia is usually determined at the end of
pregnancy or at delivery. WHO definitions for mild and
severe anaemia are a haemoglobin level below 11 g/dL
and 7 g/dL, respectively [39]. Although severe anaemia
has been shown to be associated with a higher child and
maternal morbidity and mortality, mild anaemia does not
seem to confer unquestionably higher risks for the mother
or the baby [40]. Hence, severe anaemia should be the
best indicator of the two. As the prevalence of severe anae-
mia is very low, a higher threshold could be used, such as
8 g/dL, as advocated by several authors [12,15].
Placental malarial infection is the main parasitological
indicator. Compared to LBW or maternal anaemia, it is
not multifactorial and depends only on the presence of
parasites. Some authors have suggested to check for
peripheral infections during pregnancy instead of placen-
tal infection [41]. Nevertheless, placental infection should
be more appropriate to evaluate malaria prevention strat-
egies as it is directly linked to the newborn, whom the pre-
vention is focused on. It has been shown to be highly
correlated with late peripheral infections, which are the
most deleterious for the child [22]. Besides, women can
be reached more easily at delivery than during pregnancy.
To detect placental infections, thick blood smear are more
appropriate than PCR and biopsy. Indeed, it is more easily
feasible, cheaper, and a high correlation has been found
between placental infection – determined in this way –
and low birth weight [3,15,17,42] and prematurity [20].
PCR is more sensitive to detect placental infections, but by
being too sensitive it is less discriminating when compar-
ing two drugs or strategies. Biopsy provides additional
information regarding chronic and past malaria infec-
tions, but these infections are less correlated with birth
outcomes, and it is more difficult to perform.
Such clinical indicators are of particular relevance as they
have public health implications. However, they do not
reflect the efficacy of SP-IPTp only, but the combined effi-
cacy of all the measures that benefit to pregnant women
(i.e. IPTp, ITNs and iron and folate supplementation). In
order to evaluate the IPTp strategy more specifically, the
monitoring of indicators more directly related to the drug
(such as in vivo SP efficacy) should be done at the same
time. In vivo therapeutic efficacy of antimalarials is usually
evaluated in young symptomatic children. However,
resistance rates – determined in this way – poorly corre-
late with public health delivery outcomes, in particular
because of the incomplete immune response to malaria of
children compared to adults. In a cross-sectional survey
conducted in Benin, CQ was shown to be still highly effi-
cacious to prevent LBW, while the resistance to the drug
was up to 90% in the children under five years of age liv-
ing in the same area [43]. Also, a recent study discussed
the relevance of extrapolating data collected in children to
pregnant women, as both groups showed different sensi-
tivity to drugs such as CQ or SP [44]. To collect more
meaningful data, in vivo SP efficacy should be determined
in pregnant women rather than children. In parallel, the
correlation of this protection with molecular markers of
SP resistance should be investigated.
Which alternative drugs for IPTp?
In addition, there is a need to evaluate alternative antima-
larial drugs for IPTp, in terms of efficacy, tolerability and
acceptability, to replace SP when it is considered not effi-
cacious enough to protect women.Malaria Journal 2007, 6:160 http://www.malariajournal.com/content/6/1/160
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Ideal properties for an alternative drug are: (1) having a
long-half life, as it has been suggested that IPTp had a pro-
phylactic rather than a treatment effect and that the dura-
tion of prophylaxis was the most important determinant
of IPTp efficacy; (2) being safe during pregnancy, and
well-tolerated to ensure a high compliance with the treat-
ment in women who are often asymptomatic when
infected with malaria; (3) being easy to administer (ide-
ally a single dose); and (4) at an affordable cost.
As recently stated by the WHO, mefloquine is presently
one of the most attractive options. It has a long half-life
and is still highly efficacious in African countries. Most
studies have shown that MQ was safe for use in pregnancy
[3,45-47]. A single study has suggested that women who
received MQ treatment had a significantly higher risk of
stillbirth than women not treated or treated with other
antimalarials [48]. Further studies have not confirmed
this finding so far [49]. MQ has been associated with a
range of side-effects, raising the question of the women's
compliance with the treatment. In an ongoing clinical
trial, in which Beninese women are randomized to receive
SP or MQ (15 mg/kg as a single intake) for IPTp [35], only
mild adverse events have been observed – such as vomit-
ing, nausea and dizziness, and they resolved fast (Briand,
personal communication). Very few women have refused
to take the second dose because of a poor tolerance of the
first intake. The drug has been well-accepted in spite of its
bitter taste, and there has been less than 1% of early vom-
iting (within one hour) after giving a fat snack before the
women took the drug (as recommended by the manufac-
turer).
Whatever the alternative drug, the cost will be substan-
tially higher than for SP or CQ. Mefloquine remains
expensive even if its cost has recently declined. In a near
future, lower cost and higher availability of the drug in
African countries should make this option even more real-
istic.
Artemisinin combination therapies (ACT) are also being
evaluated for IPTp. They have been shown to be highly
efficacious and safe during pregnancy except when used in
the first trimester. However, if the effect of IPTp is mainly
prophylactic [28], then short-acting drugs would be
expected to provide little benefit. Moreover, ACT are still
very expensive and less easily deliverable as they require
multiple treatment doses that could not be given as a
directly-observed therapy in the ANC clinic. Because the
treatment needs to be administered several times, compli-
ance might be low. Other potential candidates, such as SP
plus amodiaquine, SP plus azithromycine (keeping in
mind the risk of pneumococcus-resistance increase when
using azithromycine) and chlorproguanil-dapsone are
also being assessed for IPTp. Piperaquine – used in com-
binations with other antimalarials rather than used alone
– might be one of the most promising options for IPTp.
Conclusion
There is evidence that IPTp with SP is presently the most
efficacious and adequate strategy for the prevention of
malaria during pregnancy in high transmission areas.
However, several years after having been implemented
various problems have to be solved. In particular, it seems
that only some of the women exposed to malaria are ben-
efiting from this policy. Efforts should be made to
improve performance of health worker and the motiva-
tion of women and their perception of malaria complica-
tions in pregnancy. The growing resistance of parasites to
SP requires an urgent evaluation of alternative drugs to SP.
Some attention should be given to the optimal dosage
and frequency of administration, which have never been
clearly determined. Finally, as IPTp is not applicable in
early pregnancy – as most antimalarial drugs are contrain-
dicated during the first trimester – one should continue
combining the strategy with ITNs which can be applied
earlier in pregnancy, and thus could add to late preg-
nancy's measures such as IPTp.
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